To acquire 23andMe’s Personal Genome Service, Total Health and Research Services business lines, and its Biobank and ...

In its announcement of the acquisition, Regeron claimed it would ensure that customers’ personal data including genetic and ...

Regeneron acquires bankrupt 23andMe for $256M. What this DNA data sale means for privacy, pharma, and your genetic ...

American biotechnology firm Regeneron Pharmaceuticals is buying the personal genetics brand 23andMe after submitting a winning bid of $256 million in a bankruptcy auction, according to a Monday ...

Regeneron Pharmaceuticals is set to acquire substantially all assets of 23andMe for $256 million. The deal is expected to ...

The bankrupt genetic-testing firm will hand over its entire data bank, including DNA samples of around 15 million people. Regeneron has said it will abide by 23andMe’s privacy policy, allowing ...

Regeneron Pharmaceuticals will acquire embattled DNA testing company 23andMe in a $256 million court-supervised sale, ...

The sale was for $256 million and is expected to be complete by the third quarter of this year, according to a Regeneron news ...

Regeneron acquires 23andMe for $256 million following its bankruptcy. The deal includes DNA data access, raising privacy ...

In March, 23andMe said that it was looking to sell “substantially all of its assets” through a court-approved reorganization plan.

Regeneron Pharmaceuticals said in a press release yesterday that it would acquire 23andMe’s Personal Genome Service (PGS), ...